Ontology highlight
ABSTRACT:
SUBMITTER: Garg AD
PROVIDER: S-EPMC4653610 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature
Garg Abhishek D AD Galluzzi Lorenzo L Apetoh Lionel L Baert Thais T Birge Raymond B RB Bravo-San Pedro José Manuel JM Breckpot Karine K Brough David D Chaurio Ricardo R Cirone Mara M Coosemans An A Coulie Pierre G PG De Ruysscher Dirk D Dini Luciana L de Witte Peter P Dudek-Peric Aleksandra M AM Faggioni Alberto A Fucikova Jitka J Gaipl Udo S US Golab Jakub J Gougeon Marie-Lise ML Hamblin Michael R MR Hemminki Akseli A Herrmann Martin M Hodge James W JW Kepp Oliver O Kroemer Guido G Krysko Dmitri V DV Land Walter G WG Madeo Frank F Manfredi Angelo A AA Mattarollo Stephen R SR Maueroder Christian C Merendino Nicolò N Multhoff Gabriele G Pabst Thomas T Ricci Jean-Ehrland JE Riganti Chiara C Romano Erminia E Rufo Nicole N Smyth Mark J MJ Sonnemann Jürgen J Spisek Radek R Stagg John J Vacchelli Erika E Vandenabeele Peter P Vandenberk Lien L Van den Eynde Benoit J BJ Van Gool Stefaan S Velotti Francesca F Zitvogel Laurence L Agostinis Patrizia P
Frontiers in immunology 20151120
The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology of neoplastic cells. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is c ...[more]